miR‑146a‑5p targets interleukin‑1 receptor‑associated kinase 1 to inhibit the growth, migration, and invasion of breast cancer cells

Long,Jing‑Pei; Dong,Li‑Feng; Chen,Fang‑Fang; Fan,Yang‑Fan

doi:10.3892/ol.2018.9769

miR‑146a‑5p targets interleukin‑1 receptor‑associated kinase 1 to inhibit the growth, migration, and invasion of breast cancer cells

Authors:
- Jing‑Pei Long
- Li‑Feng Dong
- Fang‑Fang Chen
- Yang‑Fan Fan
View Affiliations

Affiliations: Department of Breast, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China
Published online on: November 28, 2018 https://doi.org/10.3892/ol.2018.9769
Pages: 1573-1580
Copyright: © Long et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are associated with the formation and progression of many types of cancers. In the present study, the aim was to elucidate the involvement of miR‑146a‑5p in the regulation of human breast cancer (BC) cell growth and invasion, as well as the mechanisms underlying its effects. Reverse transcription‑quantitative polymerase chain reaction results revealed that miR‑146a‑5p was markedly downregulated in BC tissues relative to those of adjacent normal tissues. miR‑146a‑5p expression was also markedly downregulated in BC cells. Overexpression of miR‑146a‑5p significantly suppressed the proliferation, invasion and migration of BC MDA‑MB‑453 and MCF7 cells. Furthermore, the results indicated that miR‑146a‑5p downregulated the expression of interleukin‑1 receptor‑associated kinase 1 (IRAK1) by directly binding to its 3'‑untranslated region in BC cells. Furthermore, IRAK1 expression was observed to be markedly upregulated and inversely correlated with miR‑146a‑5p expression in BC tissues. Mechanical studies indicated that restoring IRAK1 expression reversed the miR‑146a‑5p‑induced inhibitory effects on proliferation and invasion of BC cells. In conclusion, miR‑146a‑5p may act as a tumor suppressor in BC by directly targeting IRAK1. These results highlighted the potential of miR‑146a‑5p as a novel therapeutic target for the treatment of BC.

View Figures

View References

1	Liang Z and Xi Y: MicroRNAs mediate therapeutic and preventive effects of natural agents in breast cancer. Chin J Nat Med. 14:881–887. 2016.PubMed/NCBI
2	Chernyi VS, Tarasova PV, Kozlov VV, Saik OV, Kushlinskii NE and Gulyaeva LF: Search of MicroRNAs regulating the receptor status of breast cancer in silico and experimental confirmation of their expression in tumors. Bull Exp Biol Med. 163:655–659. 2017. View Article : Google Scholar : PubMed/NCBI
3	Lü L, Mao X, Shi P, He B, Xu K, Zhang S and Wang J: MicroRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis. Medicine. 96:e70852017. View Article : Google Scholar : PubMed/NCBI
4	Sempere LF, Keto J and Fabbri M: Exosomal MicroRNAs in breast cancer towards diagnostic and therapeutic applications. Cancers. 9(pii): E712017. View Article : Google Scholar : PubMed/NCBI
5	Li D, Wang H, Song H, Xu H, Zhao B, Wu C, Hu J, Wu T, Xie D, Zhao J, et al: The microRNAs miR-200b-3p and miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and motility of breast cancer cells. Oncotarget. 8:85276–85289. 2017.PubMed/NCBI
6	Mjelle R, Sellæg K, Sætrom P, Thommesen L, Sjursen W and Hofsli E: Identification of metastasis-associated microRNAs in serum from rectal cancer patients. Oncotarget. 8:90077–90089. 2017. View Article : Google Scholar : PubMed/NCBI
7	Awasthi R, Rathbone MJ, Hansbro PM, Bebawy M and Dua K: Therapeutic prospects of microRNAs in cancer treatment through nanotechnology. Drug Deliv Transl Res. 8:97–110. 2018. View Article : Google Scholar : PubMed/NCBI
8	Wang YN, Chen ZH and Chen WC: Novel circulating microRNAs expression profile in colon cancer: A pilot study. Eur J Med Res. 22:512017. View Article : Google Scholar : PubMed/NCBI
9	Pajic M, Froio D, Daly S, Doculara L, Millar E, Graham PH, Drury A, Steinmann A, de Bock CE, Boulghourjian A, et al: miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense. Cancer Res. 78:501–515. 2018. View Article : Google Scholar : PubMed/NCBI
10	Li J, Lai Y, Ma J, Liu Y, Bi J, Zhang L, Chen L, Yao C, Lv W, Chang G, et al: miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer. BMC Cancer. 17:7452017. View Article : Google Scholar : PubMed/NCBI
11	Zhuang C, Yuan Y, Song T, Wang H, Huang L, Luo X, He H, Huo L, Zhou H, Wang N, et al: miR-219a-5p inhibits breast cancer cell migration and epithelial-mesenchymal transition by targeting myocardin-related transcription factor A. Acta Biochim Biophys Sin. 49:1112–1121. 2017. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Wee ZN, Yatim SM, Kohlabauer VK, Feng M, Goh JY, Bao Y, Lee PL, Zhang S, Wang PP, Lim E, et al: Corrigendum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat Commun. 6:100542015. View Article : Google Scholar : PubMed/NCBI
14	Xu B, Huang Y, Niu X, Tao T, Jiang L, Tong N, Chen S, Liu N, Zhu W and Chen M: Hsa-miR-146a-5p modulates androgen-independent prostate cancer cells apoptosis by targeting ROCK1. Prostate. 75:1896–1903. 2015. View Article : Google Scholar : PubMed/NCBI
15	Yuwen DL, Sheng BB, Liu J, Wenyu W and Shu YQ: MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 21:2650–2658. 2017.PubMed/NCBI
16	Min SK, Jung SY, Kang HK, Park SA, Lee JH, Kim MJ and Min BM: Functional diversity of miR-146a-5p and TRAF6 in normal and oral cancer cells. Int J Oncol. 51:1541–1552. 2017. View Article : Google Scholar : PubMed/NCBI
17	Zhang X, Dang Y, Li P, Rong M and Chen G: Expression of IRAK1 in lung cancer tissues and its clinicopathological significance: A microarray study. Int J Clin Exp Pathol. 7:8096–8104. 2014.PubMed/NCBI
18	Ye ZH, Gao L, Wen DY, He Y, Pang YY and Chen G: Diagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: An analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlas. Onco Targets Ther. 10:1711–1723. 2017. View Article : Google Scholar : PubMed/NCBI
19	Wang Y, Wang Y, Duan X, Wang Y and Zhang Z: Interleukin-1 receptor-associated kinase 1 correlates with metastasis and invasion in endometrial carcinoma. J Cell Biochem. 119:2545–2555. 2018. View Article : Google Scholar : PubMed/NCBI
20	Chou CK, Chi SY, Huang CH, Chou FF, Huang CC, Liu RT and Kang HY: IRAK1, a target of miR-146b, reduces cell aggressiveness of human papillary thyroid carcinoma. J Clin Endocrinol Metab. 101:4357–4366. 2016. View Article : Google Scholar : PubMed/NCBI
21	Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Bao Y, Lee PL, Zhang S, Wang PP, Lim E, et al: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat Commun. 6:87462015. View Article : Google Scholar : PubMed/NCBI
22	Si C, Yu Q and Yao Y: Effect of miR-146a-5p on proliferation and metastasis of triple-negative breast cancer via regulation of SOX5. Exp Ther Med. 15:4515–4521. 2018.PubMed/NCBI